GlassScriptPhysician profile
Angela Potter
NPI 1811977317
$4,326.48
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,877 · 2022: $1,969 · 2023: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $610.97 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $476.15 | 2021-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $434.89 | 2021-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $359.00 | 2021-2023 | Shingrix |
| Abbvie INC. | $280.83 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $270.49 | 2021-2022 | |
| Pfizer INC. | $219.27 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $216.22 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $197.92 | 2022 | |
| Amgen INC. | $151.95 | 2021-2023 | Otezla, Repatha |
| Gilead Sciences, INC. | $135.30 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.13 | 2021-2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $125.10 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $114.91 | 2021-2022 | |
| Grifols USA, LLC | $110.01 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.82 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $82.21 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.56 | 2022-2023 | |
| Daiichi Sankyo INC. | $78.08 | 2021-2022 | |
| Astellas Pharma US INC | $37.26 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $33.16 | 2022 | |
| Sunovion Pharmaceuticals INC. | $22.32 | 2021 | |
| Mylan Specialty L.P. | $20.02 | 2021 | |
| Exact Sciences Corporation | $15.22 | 2023 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $13.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.87 | 2022 | |
| Amarin Pharma, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.